Arcanobacterium haemolyticum initially named C. haemolyticum, was first described by MacClean et al. in 1946 from subjects suffering from sore throat. Controversies regarding classification were solved in 1982 when a new genus, Arcanobacterium (enigmatic bacterium) was created based on its peptidoglycan, fatty acid, and DNA characteristics.
Since its initial description, the spectrum of diseases caused by A. haemolyticum has been expanded to include sepsis and osteomyelitis. Organisms are Gram-positive, facultative anaerobic, catalase negative rods (but transition to the coccal shape occurs as the organism grows) with arrangements described as matchbox or Chinese letters arrangements. Growth is enhanced in blood and by carbon dioxide.
A. haemolyticum infection is most common in 15- to 25-year-old persons and manifests as exudative pharyngitis and/or tonsillitis accompanied by cervical lymphadenopathy. Symptoms look like those of β-hemolytic streptococci or viral infection. A rash of the chest and of the abdomen, neck, or extremities is seen in 20% to 25% of cases enhancing the risk of diagnostic error as streptococcal infection or penicillin allergy, when β-lactam therapy is initiated without exact diagnosis.
A. haemolyticum often occurs in polymicrobic infections together with typical respiratory pathogens such as streptococci. The isolation of classical pathogens from specimens that also contain A. haemolyticum might be in part responsible for the tendency to miss the organism.
A. haemolyticum isolated from humans is susceptible to erythromycin (proposed as the first line drug ), clindamycin, gentamicin, and cephalosporins. The use of parenteral antimicrobial drugs must be limited to serious infections.